4296-73-5

Usage

Uses

Used in Pharmaceutical Industry:
(2Z)-4-(hydroxyamino)-4-oxobut-2-enoic acid is used as an intermediate for the production of methionine, a crucial amino acid in the pharmaceutical industry. Its role in the one-carbon metabolism pathway and sulfur-containing amino acid regulation makes it a vital component in the synthesis of various pharmaceutical compounds.
Used in Biochemical Research:
In the field of biochemical research, (2Z)-4-(hydroxyamino)-4-oxobut-2-enoic acid is utilized as a key molecule for studying the metabolic pathways involving sulfur-containing amino acids. Its involvement in the conversion of homocysteine to methionine and the synthesis of S-adenosylmethionine provides valuable insights into the regulation of these essential biochemical processes.
Used in Nutritional Supplements:
(2Z)-4-(hydroxyamino)-4-oxobut-2-enoic acid can be used as a component in the development of nutritional supplements that focus on supporting sulfur-containing amino acid metabolism and overall cellular health.
Used in Agricultural Industry:
In the agricultural industry, (2Z)-4-(hydroxyamino)-4-oxobut-2-enoic acid may be employed in the development of additives or supplements for livestock to enhance their sulfur-containing amino acid metabolism, thereby improving their overall health and productivity.

Upstream product

• 108-31-6 maleic anhydride 

Relevant academic research and scientific papers

Hydroxamic acids: synthesis and adjuvant activity in combinatorial anticancer therapy

Monoand disubstituted N-hydroxyamides of dicarboxylic acids were prepared by reaction of dicarboxylic acids or acid anhydrides with hydroxylamine. The use of these compounds in combinatorial cytostatic therapy of implanted tumors with cisplatin or cyclophosphamide totally inhibits metastasis formation in B16 melanoma and Lewis lung carcinoma, and resulted in 100% survival of leukemic animals.

DICARBONIC ACID DERIVATIVES, METASTASIS INHIBITORS AND AGENTS INCREASING CHEMOTHERAPEUTIC ACTIVITY OF ANTI-TUMOR PREPARATIONS, METHOD FOR ENHANCING THE EFFICIENCY OF CYTOSTATICS AND METASTASIS PROCESS INHIBITING METHOD

The invention relates to dicarbonic acid derivatives and concerns dicarbonic acid monooxydamines and dioxydamides, which are physiologically active substances and can be used as low-toxic and non-toxic agents for enhancing the anti-tumor and anti-metastasis effects of known cytostatics (cyclophosphane and cisplatin) in cytostatic chemotherapy of tumors. The object of the present invention is to broaden the assortment of agents affecting a live organism in order to enhance anti-tumor and anti-metastasis effects of known cytostatics. This object is resolved by the properties of dicarbonic acid monooxydamines and dioxydamides. The essence of the invention consists in that dicarbonic acid derivatives, the formulas of which are presented in the specification, are proposed as agents for enhancing anti-tumor and anti-metastasis effects of cytostatics. The claimed compounds can be used in medical practice as low-toxic agents for enhancing anti-tumor and anti-metastasis effects of known cytostatics with a simultaneous 4-fold reduction of the therapeutic dose of cytostatics. The use of the proposed compounds in a combination with cisplatin at the minimum doses makes it possible to completely inhibit the metastasis process in experimental B-16 melanoma. Furthermore, the use of the proposed compounds at the minimum doses in a combination with the minimum doses of cytostatics (when neither of the preparations alone exhibitsefficacy) makes it possible to obtain a high therapeutic effect in treating leukemias (survival of animals with P-388 leukemia in the test group is 100%).